Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101946 · ClinicalTrials.gov registry record · Phase 2
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00101946 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants.
The verdict
NCT00101946, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and safety of the investigational drug 683699 in treating subjects with moderately to severely active CD (Crohn's Disease).
Interventions
- DRUG 683699
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101946
The ClinicalTrials.gov registry entry for NCT00101946 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 683699 is the first listed.
NCT00101946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101946 about?
NCT00101946 is a clinical study titled "Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease". This study will evaluate the effectiveness and safety of the investigational drug 683699 in treating subjects with moderately to severely active CD (Crohn's Disease).
What is the current status of trial NCT00101946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00101946?
The interventions under investigation include: 683699 (DRUG).
Who is sponsoring clinical trial NCT00101946?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.